Germany to spend €750 million on coronavirus vaccine | News | DW | 11.05.2020

Visit the new DW website

Take a look at the beta version of We're not done yet! Your opinion can help us make it better.

  1. Inhalt
  2. Navigation
  3. Weitere Inhalte
  4. Metanavigation
  5. Suche
  6. Choose from 30 Languages


Germany to spend €750 million on coronavirus vaccine

The German government has agreed a funding program of three-quarters of a billion euros on the development and distribution of a coronavirus vaccine. Researchers hope large-scale trials will help speed up the process.

Germany agreed Monday to spend €750 million ($812 million) on a program to develop and distribute vaccines, Research Minister Anja Karliczek announced.

Read more: Coronavirus latest — Hard-hit Europe eases restrictions

Around half a billion euros will go towards extending the trial capacities in Germany, and the rest of the money to developing production capacity. The announcement comes following a cabinet meeting led by Chancellor Angela Merkel.

"As soon as a vaccine is found and approved, production must be able to start quickly on a large scale both here in Germany and worldwide," Karliczek said. She called vaccine development the "key" to returning to normal life.

Large-scale trials

A primary goal of the new funding program is to allow clinical trials to work with a larger number of participants from the start. Medical personnel or other essential workers could be included in the tests on a voluntary basis, Karliczek said.

Normally trials are conducted on a step-by-step basis with a small amount of participants at the beginning and are slowly expanded.

COVID-19: three different approaches to a vaccine

Germany is one of a number of countries around the world funding trials into vaccine development. According to the German-based Association of Research-Based Pharmaceutical Companies, 121 vaccine development programs are underway around the world.

ed/rc (dpa, Reuters)

Every evening at 1830 UTC, DW's editors send out a selection of the day's hard news and quality feature journalism. You can sign up to receive it directly here.

DW recommends